| 产品名称： | Vaccinia virus |
|---|---|
| 商品货号： | TS166400 |
| Classification： | Poxviridae, Orthopoxvirus |
| Agent： | Vaccinia virus |
| Strain： | CL |
| Biosafety Level： | 2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Product Format： | frozen 1 mL per vial |
| Storage Conditions： | xa0-70°C or colder |
| Comments： | VR-1774 is produced in BSC-40 cells, which is a change in cell line from ATCC VR-117 to increase titer. |
| Effect on Host： | xa0CPE, refractile cell rounding CPE, refractile cell rounding |
| Recommended Host： | Production Host: xa0BSC-40 (ATCC® CRL-2761x99) BSC-40 (ATCC CRL-2761) |
| Growth Conditions： | Temperature: 37°C Growth Conditions: Plate cells 24-48 hours in advance and infect when cultures are 90 to 95% confluent. Remove medium and inoculate with a small volume (e.g. 1 mL per 25 cm2) of virus diluted to provide an optimal MOI (e.g. 0.1). Adsorb 30 minutes at 37°C in a humidified 5% CO2 atmosphere, rocking every 7-10 minutes to redistribute inoculum. End adsorption by adding virus growth medium. Incubation: 1-3 days |
| Name of Depositor： | F Fenner, Australian National University |
| Source： | Most likely derived from New York City Department of Health strain of vaccinia virus. Cell culture adapted to BSC-40 cells. |
| References： | Fenner, F and Burnet, FM. A short description of the Poxvirus group (Vaccinia and related viruses). Virology 4: 305-314, 1957. PubMed: 13496547. Craigie J. . Br. J. Exp. Pathol. 13: 259, 1932. Parker RF, et al. Further studies of the infectious unit of Vaccinia. J. Exp. Med. 74: 263-281, 1941. |
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | Vaccinia virus |
|---|---|
| 商品货号： | TS166400 |
| Classification： | Poxviridae, Orthopoxvirus |
| Agent： | Vaccinia virus |
| Strain： | CL |
| Biosafety Level： | 2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Product Format： | frozen 1 mL per vial |
| Storage Conditions： | xa0-70°C or colder |
| Comments： | VR-1774 is produced in BSC-40 cells, which is a change in cell line from ATCC VR-117 to increase titer. |
| Effect on Host： | xa0CPE, refractile cell rounding CPE, refractile cell rounding |
| Recommended Host： | Production Host: xa0BSC-40 (ATCC® CRL-2761x99) BSC-40 (ATCC CRL-2761) |
| Growth Conditions： | Temperature: 37°C Growth Conditions: Plate cells 24-48 hours in advance and infect when cultures are 90 to 95% confluent. Remove medium and inoculate with a small volume (e.g. 1 mL per 25 cm2) of virus diluted to provide an optimal MOI (e.g. 0.1). Adsorb 30 minutes at 37°C in a humidified 5% CO2 atmosphere, rocking every 7-10 minutes to redistribute inoculum. End adsorption by adding virus growth medium. Incubation: 1-3 days |
| Name of Depositor： | F Fenner, Australian National University |
| Source： | Most likely derived from New York City Department of Health strain of vaccinia virus. Cell culture adapted to BSC-40 cells. |
| References： | Fenner, F and Burnet, FM. A short description of the Poxvirus group (Vaccinia and related viruses). Virology 4: 305-314, 1957. PubMed: 13496547. Craigie J. . Br. J. Exp. Pathol. 13: 259, 1932. Parker RF, et al. Further studies of the infectious unit of Vaccinia. J. Exp. Med. 74: 263-281, 1941. |
